SeleRNA
Pioneering cardiomyocyte-selective modRNA translation to regenerate damaged hearts and protect against chemotherapy-induced cardiotoxicity
Our CM SMRTs platform delivers therapeutic proteins directly to heart muscle cells, turning cardiomyocytes into on-site biomanufacturers
Pioneering modRNA delivery to regenerate heart tissue after myocardial infarction, with proven efficacy in both small and large animal models moving toward first-in-human trials.
Protecting the heart from chemotherapy-induced cardiotoxicity by enabling cardiomyocytes to produce protective therapeutic proteins on-site, minimizing systemic side effects.
Cardiomyocyte-selective targeting eliminates invasive gene therapy surgery and dramatically reduces off-target effects compared to traditional approaches.
Building a next-generation cardiac therapy company that transforms patient outcomes
We are developing approaches to regenerate the heart after myocardial infarction and protect it from chemotherapy-induced cardiotoxicity using our proprietary CM SMRTs platform.
Actively refining CM SMRTs delivery methods, lipid-nanoparticle composition, and dosing regimens to achieve precise, high-efficacy translation of therapeutic targets in large-animal models.
World-class expertise in cardiac regeneration and modRNA therapeutics
Founder & Principal Investigator
Associate Professor of Cardiology and Genetics at Mount Sinai's Icahn School of Medicine, Dr. Zangi holds the Chan Soon-Shiong Professorship in Cardiovascular Research. His groundbreaking work was the first to demonstrate modRNA delivery into cardiac muscle and pioneer its use to treat ischemic heart disease, showing cardiac repair and heart failure prevention in both small and large animals.